162 related articles for article (PubMed ID: 28577949)
1. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
Yotsukura M; Yasuda H; Shigenobu T; Kaseda K; Masai K; Hayashi Y; Hishida T; Ohtsuka T; Naoki K; Soejima K; Betsuyaku T; Asamura H
Lung Cancer; 2017 Jul; 109():45-51. PubMed ID: 28577949
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
[TBL] [Abstract][Full Text] [Related]
3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
4. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
Vora HH; Patel NA; Thakore PM; Shukla SN
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532
[TBL] [Abstract][Full Text] [Related]
6. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Wang Y; Li RQ; Ai YQ; Zhang J; Zhao PZ; Li YF; He WJ; Xia YX; Li WH
Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
8. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
10. Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
Hata A; Yoshioka H; Fujita S; Kunimasa K; Kaji R; Imai Y; Tomii K; Iwasaku M; Nishiyama A; Ishida T; Katakami N
J Thorac Oncol; 2010 Oct; 5(10):1524-8. PubMed ID: 20808254
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
12. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma.
Isaka T; Nakayama H; Yokose T; Ito H; Miyagi Y; Matsuzaki T; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Masuda M
Ann Thorac Surg; 2016 Dec; 102(6):1821-1828. PubMed ID: 27553497
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma.
Yang F; Sun K; Li F; Li X; Shi J; Sun X; Hong Y; Jiang G; Zhu Y; Song X
Ann Thorac Surg; 2024 Jun; 117(6):1111-1119. PubMed ID: 37353101
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns.
Hsu KH; Chen KC; Yang TY; Yeh YC; Chou TY; Chen HY; Tsai CR; Chen CY; Hsu CP; Hsia JY; Chuang CY; Tsai YH; Chen KY; Huang MS; Su WC; Chen YM; Hsiung CA; Chang GC; Chen CJ; Yang PC
J Thorac Oncol; 2011 Jun; 6(6):1066-72. PubMed ID: 21512404
[TBL] [Abstract][Full Text] [Related]
17. Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
Katayama T; Matsuo K; Kosaka T; Sueda T; Yatabe Y; Mitsudomi T
Surg Oncol; 2010 Dec; 19(4):e144-9. PubMed ID: 20705455
[TBL] [Abstract][Full Text] [Related]
18. CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.
Ozkan E; West A; Dedelow JA; Chu BF; Zhao W; Yildiz VO; Otterson GA; Shilo K; Ghosh S; King M; White RD; Erdal BS
AJR Am J Roentgenol; 2015 Nov; 205(5):1016-25. PubMed ID: 26496549
[TBL] [Abstract][Full Text] [Related]
19. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
[TBL] [Abstract][Full Text] [Related]
20. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
Isaka T; Ito H; Nakayama H; Yokose T; Saito H; Adachi H; Miura J; Shigefuku S; Kikuchi A; Rino Y
Lung Cancer; 2021 Dec; 162():128-134. PubMed ID: 34775216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
